The EphA4 receptor has been proposed to be a key actor in neurodegenerative diseases. In the last years, several research groups focused their efforts on the discovery of small molecules capable of blocking EphA4 activity by binding its extracellular domain. However, none of the compounds so far identified possess adequate chemical and/or pharmacological profiles to assess the "druggability" of EphA4 in animal models. New efforts are required to deliver a new generation of suitable pharmacological tools.

Are we using the right pharmacological tools to target EphA4? / Tognolini, Massimiliano; Incerti, Matteo; Lodola, Alessio. - In: ACS CHEMICAL NEUROSCIENCE. - ISSN 1948-7193. - 5:12(2014), pp. 1146-7-1147. [10.1021/cn500285h]

Are we using the right pharmacological tools to target EphA4?

TOGNOLINI, Massimiliano
;
INCERTI, Matteo;LODOLA, Alessio
2014

Abstract

The EphA4 receptor has been proposed to be a key actor in neurodegenerative diseases. In the last years, several research groups focused their efforts on the discovery of small molecules capable of blocking EphA4 activity by binding its extracellular domain. However, none of the compounds so far identified possess adequate chemical and/or pharmacological profiles to assess the "druggability" of EphA4 in animal models. New efforts are required to deliver a new generation of suitable pharmacological tools.
Are we using the right pharmacological tools to target EphA4? / Tognolini, Massimiliano; Incerti, Matteo; Lodola, Alessio. - In: ACS CHEMICAL NEUROSCIENCE. - ISSN 1948-7193. - 5:12(2014), pp. 1146-7-1147. [10.1021/cn500285h]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2788311
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact